89 related articles for article (PubMed ID: 10464675)
1. HER-2/neu oncogene amplification in cervical cancer studied by fluorescent in situ hybridization.
Mark HF; Feldman D; Das S; Sun CL; Samy M; Lathrop J
Genet Test; 1999; 3(2):237-42. PubMed ID: 10464675
[TBL] [Abstract][Full Text] [Related]
2. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
Afify AM; Werness BA; Mark HF
Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
[TBL] [Abstract][Full Text] [Related]
3. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer.
Mark HF; Feldman D; Das S; Kye H; Mark S; Sun CL; Samy M
Exp Mol Pathol; 1999 Jun; 66(2):170-8. PubMed ID: 10409446
[TBL] [Abstract][Full Text] [Related]
4. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
Akhdar A; Bronsard M; Lemieux R; Geha S
Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
Persons DL; Borelli KA; Hsu PH
Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
[TBL] [Abstract][Full Text] [Related]
6. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
Hammock L; Lewis M; Phillips C; Cohen C
Hum Pathol; 2003 Oct; 34(10):1043-7. PubMed ID: 14608539
[TBL] [Abstract][Full Text] [Related]
7. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
[TBL] [Abstract][Full Text] [Related]
8. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between aneuploidy of chromosome 17 and amplification of HER-2/neu gene in the different histological type of breast cancer].
Kuroso K; Ueda Y; Mori Y
Rinsho Byori; 2004 Nov; 52(11):897-9. PubMed ID: 15658468
[TBL] [Abstract][Full Text] [Related]
10. Her-2/neu gene amplification and protein expression in primary male breast cancer.
Rudlowski C; Friedrichs N; Faridi A; Füzesi L; Moll R; Bastert G; Rath W; Büttner R
Breast Cancer Res Treat; 2004 Apr; 84(3):215-23. PubMed ID: 15026619
[TBL] [Abstract][Full Text] [Related]
11. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
12. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.
Wang S; Hossein Saboorian M; Frenkel EP; Haley BB; Siddiqui MT; Gokaslan S; Hynan L; Ashfaq R
Mod Pathol; 2002 Feb; 15(2):137-45. PubMed ID: 11850542
[TBL] [Abstract][Full Text] [Related]
13. Assessment of chromosome 8 copy number in cervical cancer by fluorescent in situ hybridization.
Mark HF; Feldman D; Samy M; Sun C; Das S; Mark S; Lathrop J
Exp Mol Pathol; 1999 Jun; 66(2):157-62. PubMed ID: 10409444
[TBL] [Abstract][Full Text] [Related]
14. Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma.
Persons DL; Arber DA; Sosman JA; Borelli KA; Slovak ML
Anticancer Res; 2000; 20(3B):1965-8. PubMed ID: 10928135
[TBL] [Abstract][Full Text] [Related]
15. Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens.
Lin F; Shen T; Prichard JW
Diagn Cytopathol; 2005 Dec; 33(6):376-80. PubMed ID: 16299744
[TBL] [Abstract][Full Text] [Related]
16. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification.
Lal P; Salazar PA; Ladanyi M; Chen B
J Mol Diagn; 2003 Aug; 5(3):155-9. PubMed ID: 12876205
[TBL] [Abstract][Full Text] [Related]
17. Fluorescent in situ hybridization study of c-myc oncogene copy number in prostate cancer.
Mark HF; Samy M; Santoro K; Mark S; Feldman D
Exp Mol Pathol; 2000 Feb; 68(1):65-9. PubMed ID: 10640455
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu gene amplification in stages I-IV breast cancer detected by fluorescent in situ hybridization.
Mark HF; Aswad B; Bassily N; Taylor W; Brown S; Sun CL; Samy M; Zolnierz K; Wong E; Bland KI; Hsu PH
Genet Med; 1999; 1(3):98-103. PubMed ID: 11336460
[TBL] [Abstract][Full Text] [Related]
19. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.
Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR
Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175
[TBL] [Abstract][Full Text] [Related]
20. HER-2/neu amplification and overexpression in endometrial carcinoma.
Rolitsky CD; Theil KS; McGaughy VR; Copeland LJ; Niemann TH
Int J Gynecol Pathol; 1999 Apr; 18(2):138-43. PubMed ID: 10202671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
